Literature DB >> 1717612

Junctional epidermolysis bullosa keratinocytes in culture display adhesive, structural, and functional abnormalities.

J G Krueger1, A N Lin, I Leong, D M Carter.   

Abstract

An unusual, elongated, refractile cell morphology was observed in keratinocytes cultured from three patients with non-lethalis forms of junctional epidermolysis bullosa (JEB). To determine whether these changes might be related to altered cell adhesion, keratinocyte strains established from one patient were examined for adhesive, structural, and functional characteristics. JEB keratinocytes expressed keratin tonofilaments, as determined by staining with AE1 monoclonal antibodies and direct observation of tonofilaments by electron microscopy. JEB keratinocytes showed diminished cell-substratum adhesions, judged by interference reflection microscopy. Areas of diminished cell-substratum adhesion corresponded to F-actin-rich cell adhesions (focal adhesions) and not to cellular areas that abundantly express hemidesmosomal antigens. Analysis of cell-substratum adhesion by electron microscopy revealed extensive areas of cell-substratum separation in JEB keratinocytes that were not present in normal keratinocytes maintained in serum-free medium. Normal keratinocytes displayed numerous regions of focal contact between the ventral plasma membrane and the culture substratum, but these structures were not seen in JEB keratinocytes. Bundled actin filaments (stress fibers) were greatly diminished in expected regions of cell-substratum adhesion in JEB keratinocytes and, instead, displayed disorganized individual filaments. The growth rate of JEB keratinocytes was quite slow in culture, with a population doubling time of 2.7 d versus 1.5 d for normal keratinocytes under identical conditions. JEB keratinocytes also displayed a reduced ability to aggregate into colonies upon exposure to medium with increased extracellular calcium. JEB keratinocytes thus display adhesive, structural, and functional abnormalities that suggest this cell type may be central to the pathogenesis of junctional epidermolysis bullosa. Study of affected keratinocytes could be important to characterize associated molecular pathologies.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1717612     DOI: 10.1111/1523-1747.ep12491525

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  5 in total

1.  Gentamicin induces LAMB3 nonsense mutation readthrough and restores functional laminin 332 in junctional epidermolysis bullosa.

Authors:  Vadim Lincoln; Jon Cogan; Yingping Hou; Michaela Hirsch; Michelle Hao; Vitali Alexeev; Michele De Luca; Laura De Rosa; Johann W Bauer; David T Woodley; Mei Chen
Journal:  Proc Natl Acad Sci U S A       Date:  2018-06-26       Impact factor: 11.205

2.  Altered expression of a new antigen of the dermal-epidermal junction (NU-T2 DEJ Ag) in junctional epidermolysis bullosa.

Authors:  G Tadini; J Kanitakis; R Cavalli; D Schmitt; S Cambiaghi; E Berti
Journal:  Arch Dermatol Res       Date:  1995       Impact factor: 3.017

3.  E-cadherin distribution in interleukin 6-induced cell-cell separation of ductal breast carcinoma cells.

Authors:  I Tamm; I Cardinale; T Kikuchi; J G Krueger
Journal:  Proc Natl Acad Sci U S A       Date:  1994-05-10       Impact factor: 11.205

4.  Human Umbilical Cord Lining-Derived Epithelial Cells: A Potential Source of Non-Native Epithelial Cells That Accelerate Healing in a Porcine Cutaneous Wound Model.

Authors:  Jonah Ee Hsiang Kua; Chun Wei Siow; Wee Keng Lim; Jeyakumar Masilamani; Monica Suryana Tjin; Joe Yeong; Tony Kiat Hon Lim; Toan Thang Phan; Alvin Wen Choong Chua
Journal:  Int J Mol Sci       Date:  2022-08-10       Impact factor: 6.208

5.  Gentamicin Induces Laminin 332 and Improves Wound Healing in Junctional Epidermolysis Bullosa Patients with Nonsense Mutations.

Authors:  Andrew Kwong; Jon Cogan; Yingping Hou; Richard Antaya; Michelle Hao; Gene Kim; Vadim Lincoln; Qiuyang Chen; David T Woodley; Mei Chen
Journal:  Mol Ther       Date:  2020-03-17       Impact factor: 11.454

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.